Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some short-term impacts from President Donald Trump’s proposed tariffs.
Novo Nordisk (NVO), the maker of the popular diabetes and weight-loss drugs Ozempic and Wegovy, expects at least some short-term impacts from President Donald Trump’s proposed tariffs.Read more…